Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;8(1):25-32.
doi: 10.1177/2045125317734977. Epub 2017 Oct 25.

Treatment of adult ADHD: a clinical perspective

Josh Geffen  1 , Kieran Forster  2
Affiliations
Review

Treatment of adult ADHD: a clinical perspective

Josh Geffen et al. Ther Adv Psychopharmacol. 2018 Jan.

Abstract

Adult attention deficit/hyperactivity disorder (ADHD) has moved from the blurred edge of clinical focus to clear recognition as a prevalent and significant disorder in its own right. It is a relatively common comorbidity which if identified and treated may open the door to better outcomes for hard-to-treat patients. Conversely, failure to identify and treat adult ADHD is linked to negative outcomes. The recognition of the importance of adult ADHD in a subset of our patients challenges us to overcome our anxiety about this diagnosis and prevent the societal marginalization of vulnerable patients. Adult ADHD responds well to integrated pharmacological and psychotherapeutic intervention. Its treatment responsiveness reduces disability and allows the comorbidity which is typically present to be addressed. Mastering this challenge can make the diagnosis and treatment of adult ADHD a rewarding experience.

Keywords: ADHD; Adult ADHD; co-morbid; non-pharmacological; non-stimulant; stimulant; treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: This invited article is from clinicians with a specialty interest in adult ADHD. We believe our Australian urban practice is typical of first-world experience in this evolving field. Although the views expressed are entirely personal, they are informed by evidence, expert opinion and clinical experience. Dr Geffen declares no current conflicts. He has received payment for advisory board membership (Pfizer) and educational speaker fees (Servier, Lilly, Janssen, Organon, Lundbeck, Shire, Pfizer, Astra Zeneca). Dr Forster declares no competing interests.

References

    1. Caye A, Spadini AV, Karam RG, et al. Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis. Eur Child Adolesc Psychiatry 2016; 25: 1151–1159. - PubMed
    1. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164: 942–948. - PubMed
    1. Ramos-Quiroga JA, Montoya A, Kutzelnigg A, et al. Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines. Curr Med Res Opin 2013; 29: 1093–1104. - PubMed
    1. Faraone SV, Biederman J. Can attention-deficit/hyperactivity disorder onset occur in adulthood? JAMA Psychiatry 2016; 73: 655–656. - PubMed
    1. Moffitt TE, Houts R, Asherson P, et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry 2015; 172: 967–977. - PMC - PubMed

LinkOut - more resources